Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
This is a Monocentric, Prospective, Randomized, Open-label, Comparative, Phase IV Study, to
compare the effects of Vildagliptin and Gliclazide MR on Markers of Bone Remodeling, Bone
Mineral Density and Glycemic Variability in Postmenopausal Women with Type 2 Diabetes.
A total of 38 women with documented Type 2 Diabetes and menopause will be enrolled. The
active treatment will include a 50 mg dose of vildagliptin OD twice a day. As comparator,
gliclazide MR will be administered at a dose of 60 to 120 mg OD once a day.